<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156254">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01728792</url>
  </required_header>
  <id_info>
    <org_study_id>INV-DEN-105</org_study_id>
    <nct_id>NCT01728792</nct_id>
  </id_info>
  <brief_title>Impact of SQ vs IM Administration of DENVax on Safety and Immunogenicity</brief_title>
  <official_title>Impact of Subcutaneous Versus Intramuscular Administration of Inviragens Live Attenuated Dengue Vaccine on Safety and Immunogenicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inviragen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Inviragen Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the Safety and Immunogenicity of DENVax vaccination via SC or IM
      administration with needle/syringe or needle-less injector
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Adverse events including injection site reactions.</measure>
    <time_frame>Each study visit from baseline to day 120.</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viremia and neutralizing antibodies will measured.</measure>
    <time_frame>Days 30 and 120</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SQ DENVax using needle/syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM DENVax using needle/syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM DENVax using needle/syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SQ DENVax using needless injector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM DENVax using needless injector</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DENVax</intervention_name>
    <description>DENVax is a live attenuated Dengue vaccine</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health as determined by medical history, physical examination and laboratory
             tests

          -  Negative for HIV, Hepatitis B &amp; C

        Exclusion Criteria:

          -  History of Dengue fever, Japanese encephalitis, West Nile or Yellow Fever disease

          -  Seropositivity to dengue or West Nile virus

          -  Extensive scarring or tattoo (&gt; 50%) on arms, shoulders, neck face and head

          -  History of significant dermatologic disease in the last 6 months

          -  Receipt or planned receipt of any vaccine in the 4 weeks preceding or following the
             vaccinations

          -  Use of systemic corticosteroids therapy within the previous 6 months (at a dose of
             0.5 mg/kg/day).  Topical prednisone is not permitted if currently in use or used
             within the last month.

          -  Planned donation of blood during the period of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Polhemus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Upstate Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Normal</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
